| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6399632 (Pediatric) | CHATTEM SANOFI | Method of providing an antihistaminic effect in a hepatically impaired patient |
Nov, 2012
(11 years ago) | |
|
US6187791 (Pediatric) | CHATTEM SANOFI | Method of providing an antihistaminic effect in a hepatically impaired patient |
Nov, 2012
(11 years ago) | |
| US5578610 | CHATTEM SANOFI | Piperidine derivatives |
Nov, 2013
(10 years ago) | |
| US7138524 | CHATTEM SANOFI | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
May, 2014
(9 years ago) | |
| US7135571 | CHATTEM SANOFI | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
May, 2014
(9 years ago) | |
|
US5578610 (Pediatric) | CHATTEM SANOFI | Piperidine derivatives |
May, 2014
(9 years ago) | |
|
US7135571 (Pediatric) | CHATTEM SANOFI | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
Nov, 2014
(9 years ago) | |
|
US7138524 (Pediatric) | CHATTEM SANOFI | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
Nov, 2014
(9 years ago) | |
| US6113942 | CHATTEM SANOFI | Pharmaceutical composition for piperidinoalkanol compounds |
Feb, 2015
(9 years ago) | |
| US5932247 | CHATTEM SANOFI | Pharmaceutical composition for piperidinoalkanol compounds |
Feb, 2015
(9 years ago) | |
| US5855912 | CHATTEM SANOFI | Pharmaceutical compositions for piperidinalkanol compounds |
Feb, 2015
(9 years ago) | |
|
US5855912 (Pediatric) | CHATTEM SANOFI | Pharmaceutical compositions for piperidinalkanol compounds |
Aug, 2015
(8 years ago) | |
|
US6113942 (Pediatric) | CHATTEM SANOFI | Pharmaceutical composition for piperidinoalkanol compounds |
Aug, 2015
(8 years ago) | |
|
US5932247 (Pediatric) | CHATTEM SANOFI | Pharmaceutical composition for piperidinoalkanol compounds |
Aug, 2015
(8 years ago) | |
| US6037353 | CHATTEM SANOFI | Method of providing an antihistaminic effect in a hepatically impaired patient |
Mar, 2017
(7 years ago) | |
|
US6037353 (Pediatric) | CHATTEM SANOFI | Method of providing an antihistaminic effect in a hepatically impaired patient |
Sep, 2017
(6 years ago) | |
Allegra Hives is owned by Chattem Sanofi.
Allegra Hives contains Fexofenadine Hydrochloride.
Allegra Hives has a total of 16 drug patents out of which 16 drug patents have expired.
Expired drug patents of Allegra Hives are:
- US6399632*PED
- US6187791*PED
- US5578610
- US7138524
- US7135571
- US5578610*PED
- US7135571*PED
- US7138524*PED
- US6113942
- US5932247
- US5855912
- US5855912*PED
- US6113942*PED
- US5932247*PED
- US6037353
- US6037353*PED
Allegra Hives was authorised for market use on 24 January, 2011.
Allegra Hives is available in tablet;oral dosage forms.
Allegra Hives can be used as relief of symptoms associated with respiratory allergies and for the relief of symptoms associated with hives (urticaria) in adults and children 6 years of age and older and 12 years of age and older.
The generics of Allegra Hives are possible to be released after 14 September, 2017.
Drugs and Companies using FEXOFENADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 24 January, 2011
Treatment: Relief of symptoms associated with respiratory allergies and for the relief of symptoms associated with hives (urticaria) in adults and children 6 years of age and older and 12 years of age and older
Dosage: TABLET;ORAL
ALLEGRA HIVES family patents
